ANN ARBOR, Mich. May 12, 2005 -- Although under the radar of some investors, Velcura Therapeutics®, Inc. clearly has been busy since Windhover Information Inc. Review of Emerging Medical Ventures profiled the company in its piece "Drugs that Induce Bone Growth: The Beginning of An Era for Anabolic Bone Forming Agents." So Windhover's Start-Up Forum 2005 will uncover some of the recent achievements and future plans of the biotechnology company that may provide the answer for more than 44 million people who are at risk of osteoporosis, and a potential $65 billion market.

Velcura Therapeutics President and CEO Michael W. Long, Ph.D. will present the company at the event. A copy of Dr. Long's presentation will be posted on the Windhover site and at the company's Web site www.velcura.com after May 20. "Velcura has an orally available drug that both stimulates bone formation and inhibits its loss making it an excellent therapy for osteoporosis" said Dr. Long. "The Start-up Forum is a unique opportunity to speak to some of the nation's leading investors regarding the development of this therapy."

A former professor and researcher at the University of Michigan, Dr. Long and his team discovered how to grow human bone outside the body. He went on to use this intellectual property to build a company named for its goal of finding "swift cures" (Latin: Velocitas Cura) for those suffering from osteoporosis and other bone diseases.

About Velcura Therapeutics®, Inc.

Velcura Therapeutics® focuses on developing drugs that stimulate bone formation and is based in Ann Arbor, Mich. Velcura grows human bone outside the body and analyzes this process to develop novel therapies for osteoporosis and other bone diseases. The company received $3.3 million in funding from the Michigan Life Sciences Corridor in 2002 and more than $2.1 million in grants from the National Institutes of Health.